• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, February 2, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

New findings offer improved therapy of early-stage, BRCA mutation-associated breast cancer

Bioengineer by Bioengineer
June 4, 2021
in Chemistry
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Houston Methodist expert who led US component of trial available to address eagerly anticipated OlympiA trial results

IMAGE

Credit: Houston Methodist

HOUSTON-(June 3, 2021) – Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.

Titled “Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer,” the paper appears in the June 3 issue of the New England Journal of Medicine and will be presented June 6 as the first abstract during the plenary session at the 2021 American Association of Clinical Oncology (ASCO) Annual Meeting. Lead author and the OlympiA trial steering committee chair Andrew Tutt, M.D., Ph.D., of The Institute of Cancer Research and King’s College London was principal investigator on the portion of study conducted in patients outside the U.S. and will present the results at ASCO.

Led by top experts in BRCA-associated breast cancer from around the world, the OlympiA trial’s co-chairs were Charles E. Geyer, Jr., M.D., a breast medical oncologist and deputy director of the Houston Methodist Cancer Center, Judy E. Garber, M.D., M.P.H., of the Dana-Farber Cancer Institute, and Bella Kaufman, M.D., of the Sheba Medical Center in Israel. Geyer was the principal investigator on the NCI-sponsored portion of the study conducted in the U.S.

“OlympiA represents a successful global collaboration among leading international academic breast cancer research groups, cancer genetics experts, the National Cancer Institute and pharmaceutical industry partners to evaluate the efficacy and safety of olaparib to address the unmet need for improved therapy for individuals with high-risk, BRCA mutation-associated early breast cancer,” said Geyer, who also is a professor of medicine in oncology with the Houston Methodist Research Institute and has provided scientific leadership on the trial since 2013.

The OlympiA trial was a tremendous effort recruiting 1,836 patients from 420 centers across 23 countries. A randomized double-blind phase 3 trial, OlympiA was designed to test the efficacy of the Poly(ADP-ribose)-polymerase (PARP) inhibitor drug olaparib and showed that it significantly improved invasive and distant disease-free survival when given for 52 weeks following the completion of such standard therapies as chemotherapy, surgery and radiation.

Patients were recruited from June 2014 through May 2019, and patients who consented to participate were randomly assigned to receive olaparib or a placebo. After three years following initiation of treatment with olaparib, 85.9% of patients were alive and free of recurrent, invasive breast cancer and new second cancers, compared with 77.1% of patients who received a placebo. During this same timeframe, 87.5% of patients receiving olaparib were alive and free of distant metastatic disease, compared to 80.4% on the placebo.

While olaparib was also associated with 27 fewer deaths than those on placebo, researchers say longer blinded follow up is required to assess the impact of this therapy on overall survival. What is certain, say researchers, is that germline BRCA1 and BRCA2 sequencing is becoming an important biomarker for the selection of systemic therapy in early breast cancer.

###

The study was supported by funding from the U.S. National Cancer Institute (grants U10CA180868, UG1CA189867, U10CA180822) and AstraZeneca as part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp (ClinicalTrials.gov NCT02032823). The study was coordinated by the Breast International Group in academic partnership with Frontier Science & Technology Research Foundation and NRG Oncology (BIG 6-13, NSABP B-55).

Note to journalists: To speak with Charles E. Geyer, Jr., M.D., you can contact Lisa Merkl (o: 832-667-5916, c: 281-620-2502, e: [email protected]) or Ashley White (o: 832-667-5849, c: 832-652-1173, e: [email protected]) with the Houston Methodist media relations team.

For more information: Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer. New England Journal of Medicine. (online June 3) Andrew N.J. Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa Korde, Barbro Linderholm, Hanna Bandos, El?bieta Senkus-Konefka, Jennifer Marie Suga, Zhimin Shao, Andrew William Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita Schmutzler, Guenther Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer, Jr., for the OlympiA Clinical Trial Investigators. DOI: https://www.nejm.org/doi/full/10.1056/NEJMoa2105215

Media Contact
Lisa Merkl
[email protected]

Related Journal Article

http://dx.doi.org/10.1056/NEJMoa2105215

Tags: Breast CancercancerClinical TrialsDiagnosticsGynecologyHealth ProfessionalsMedicine/HealthMortality/LongevityPharmaceutical Science
Share12Tweet8Share2ShareShareShare2

Related Posts

University of Houston researchers Chandra Mohan and Richard Willson

Early diagnosis and monitoring of lupus nephritis – on your smartphone

February 1, 2023
Assistant Professor Jo Philips

Uncovering the secrets of electron-eating microorganisms

February 1, 2023

Anna Lee appointed AIP Foundation Executive Director

February 1, 2023

First solid scientific evidence that Vikings brought animals to Britain

February 1, 2023
Please login to join discussion

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    65 shares
    Share 26 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    58 shares
    Share 23 Tweet 15
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tuberculosis vaccine does not protect elderly against COVID-19

Flue2Chem: Science-based industries join forces for first time to address UK net zero targets

What’s that sound? Automobile horn changed history and communications technology

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In